Antagonist anti-CD40 antibody CHIR-12.12 causes tumor regression and prolongs survival in multiple myeloma xenograft models.

被引：0
|
作者：
Long, L [1 ]
Tong, X [1 ]
Patawaran, M [1 ]
Aukerman, L [1 ]
Jallal, B [1 ]
Luqman, M [1 ]
机构：
[1] Chiron Corp, Emeryville, CA 94608 USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.4888.4888
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4888
引用
收藏
页码：304B / 304B
页数：1
相关论文
共 50 条
  • [1] Antagonist anti-CD40 antibody, CHIR-12.12, induces ADCC, inhibits tumor growth, and prolongs survival in a human multiple myeloma xenograft model.
    Long, L
    Tong, X
    Patawaran, M
    Aukerman, SL
    Jallal, B
    Luqman, M
    BLOOD, 2005, 106 (11) : 968A - 968A
  • [2] Safety evaluation of an fully human antagonist anti-CD40 antibody, CHIR-12.12, in a dose range-finding study in cynomolgus monkeys
    Jeffry, UB
    Huh, K
    Tong, X
    Klinger, J
    Frings, W
    Fuchs, A
    Turner, N
    Luqman, M
    BLOOD, 2004, 104 (11) : 897A - 897A
  • [3] A phase I dose escalation study of a fully human, antagonist Anti-CD40 antibody, HCD122 (formerly CHIR-12.12) in patients with relapsed and refractory multiple myeloma.
    Bensinger, William
    Jagannath, Sundar
    Becker, Pamela S.
    Anderson, Kenneth C.
    Stadtmauer, Edward A.
    Aukerman, Lea
    Fox, Judith
    Girish, Sandhva
    Bilic, Sanela
    Guzy, Serge
    Solinger, Alan
    Dort, Sherri
    Wang, Yongyu
    Hurst, Deborah
    BLOOD, 2006, 108 (11) : 1021A - 1021A
  • [4] Antagonist anti-CD40 monoclonal antibody, CHIR-12.12, inhibits growth of a rituximab-resistant NHL xenograft model and achieves synergistic activity when combined with ineffective rituximab
    Long, L
    Tong, X
    Patawaran, M
    Aukerman, L
    Klinger, J
    Jallal, B
    Luqman, M
    BLOOD, 2004, 104 (11) : 896A - 897A
  • [5] Human antagonistic anti-CD40 antibody, CHIR-12.12, inhibits CD40-mediated survival of chronic lymphocytic leukemia B cells leading to cellular apoptosis
    Cherukuri, A
    Kadel, E
    Lee, SH
    Goldbeck, C
    Heise, C
    Luqman, M
    Aukerman, SL
    Aziz, N
    O'Brien, S
    Wierda, WG
    Jallal, B
    BLOOD, 2005, 106 (11) : 832A - 832A
  • [6] Comparative efficacy of rituximab and a fully human anti-CD40 antagonist antibody in in vitro and in xenograft lymphoma models.
    Long, L
    Tong, X
    Patawaran, M
    Luqman, M
    BLOOD, 2003, 102 (11) : 646A - 646A
  • [7] Immunological profile and safety evaluation in a 23-week single dose study in cynomolgus monkey with CHIR-12.12, a fully human antagonist anti-CD40 antibody.
    Jeffry, UB
    Luqman, M
    Huh, K
    Klinger, J
    Brings, W
    Turner, N
    BLOOD, 2004, 104 (11) : 243B - 243B
  • [8] A fully human anti-CD40 antagonistic antibody, CHIR-12.12, inhibit the proliferation of human B cell non-Hodgkin's lymphoma
    Weng, WK
    Tong, X
    BLOOD, 2004, 104 (11) : 896A - 896A
  • [9] In vitro activity of a novel fully human anti-CD40 antibody CHIR-12.12 in chronic lymphocytic leukemia:: Blockade of CD40 activation and induction of ADCC.
    Tong, X
    Georgakis, GV
    Li, L
    Susan, O
    Anas, Y
    Mohammad, L
    BLOOD, 2004, 104 (11) : 686A - 686A
  • [10] CHIR-12.12, an antagonist anti-CD40 antibody, exhibits greater ADCC than rituximab against a variety of malignant B cells:: Evaluation of FcγRIIIa polymorphism and ADCC response.
    Luqman, M
    Tong, X
    Niu, XH
    Garcia, P
    Faure, M
    Yabannavar, A
    Jallal, B
    BLOOD, 2005, 106 (11) : 424A - 425A
12345